Zacks Investment Research upgraded shares of United Therapeutics (NASDAQ:UTHR) from a hold rating to a buy rating in a research report sent to investors on Monday morning. Zacks Investment Research currently has $160.00 target price on the biotechnology company’s stock.
According to Zacks, “United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company, at present, has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Several data read-outs and regulatory updates are expected in 2018. However, increased competitive pressure from Uptravi on its PAH drugs, mainly Orenitram, is a concern. We believe the company needs to use cash suitably to deal with generic competition for Remodulin that could materialize post Jun 2018. However, United Therapeutics’ shares have outperformed the industry in the past six months. Estimates have gone up ahead of the Q4 earnings release. The company has a mixed record of earnings surprises in the recent quarters. “
Other equities analysts have also recently issued research reports about the company. TheStreet upgraded United Therapeutics from a c+ rating to a b rating in a report on Friday, December 15th. ValuEngine upgraded United Therapeutics from a hold rating to a buy rating in a report on Thursday, November 30th. Cowen restated a hold rating and set a $129.00 target price on shares of United Therapeutics in a report on Friday, October 27th. HC Wainwright restated a hold rating and set a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Finally, BidaskClub upgraded United Therapeutics from a sell rating to a hold rating in a report on Wednesday, December 6th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $140.45.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The firm had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. During the same quarter last year, the business earned $4.23 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. sell-side analysts anticipate that United Therapeutics will post 12.96 earnings per share for the current year.
In related news, Director Christopher Causey sold 580 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $134.72, for a total value of $78,137.60. Following the sale, the director now owns 1,555 shares of the company’s stock, valued at approximately $209,489.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,263 shares of United Therapeutics stock in a transaction that occurred on Thursday, October 26th. The shares were sold at an average price of $120.38, for a total value of $152,039.94. Following the completion of the sale, the chief executive officer now directly owns 1,403 shares in the company, valued at approximately $168,893.14. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,773 shares of company stock worth $1,925,637. 7.80% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in UTHR. Quantbot Technologies LP raised its position in United Therapeutics by 537.3% in the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 822 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in United Therapeutics in the 3rd quarter valued at approximately $156,000. Toronto Dominion Bank raised its position in United Therapeutics by 244.7% in the 3rd quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 1,351 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. acquired a new stake in United Therapeutics in the 3rd quarter valued at approximately $233,000. Finally, TLP Group LLC acquired a new stake in United Therapeutics in the 2nd quarter valued at approximately $246,000.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.